Abstract: Alzheimer disease (AD) can be considered the most common age-related neurodegenerative disorder, and also, an important cause of death in elderly patients. A number of studies found the correlation of this disease pathology with BACE1 inhibitor and it is also evident that BACE1 inhibitor can function as a very potent treatment strategy in treating AD. In the present study, we aimed to prospect for novel plant-derived BACE1 inhibitors from Leea indica and to realize the structural basis of their interactions and mechanisms using combined molecular docking and molecular dynamics based approaches. An extensive library of Leea indica plant-derived molecule was compiled and computationally screened for inhibitory action against BACE1 by using virtual screening approaches. Furthermore, induced fit docking and classical molecular dynamics along with steered molecular dynamics simulations were employed to get insight the binding mechanisms. Two triterpenoids, ursolic acid and lupeol were identified through virtual screening; wherein, lupeol showed better binding free energy in MM/GBSA, MM/PBSA and MM/GBVI approaches. Furthermore classical and steered dynamics revealed the favourable hydrophobic interactions between the lupeol and the residues of flap or catalytic dyad of BACE1; however, ursolic acid showed disfavorable interactions with the BACE1. This study, therefore, unveiled the lupeol as a potent BACE1 inhibitor from a manually curated dataset of Leea indica molecules, which may provide a new dimension of designing novel BACE1 inhibitors for AD therapy.
INTRODUCTION
The most common, irreversible, progressive form of neurological disease -Alzheimer's disease, which is characterized mainly by short-term memory loss and other behavioural disturbances most generally in elderly people [1] . It is a slowly progressing disease linked with synapse loss and neurodegeneration leading to the cognitive problems, memory impairment, difficulties with thinking, delusions [2] , problem solving or language, loss of reasoning skills, pathophysiological abnormalities, personality and behavioural changes [3] , vascular brain injury (VBI), Lewy body disease (LBD) and hippocampal sclerosis (HS) [4, 5] . The two most critical histopathological features observed in case of AD and connected with pathogenesis and diagnosis are accumulation of β-amyloid (Aβ) plaques and flame-shaped neurofibrillary tangles in the brain [6] . The presence of neuritic plaques composed (in large part) of highly insoluble Aβ in the brain parenchyma is required for the diagnosis of AD [7] . The hypothesis of amyloid cascade states that Aβ, which is created by two proteolytic cleavages of the large transmembrane protein amyloid precursor protein (APP) is critical for the development of AD pathology [6] . APP is catabolized by the β-and γ-secretase to excise Aβ and released outside the cell, as well as accumulated, when the metabolic ability to degrade Aβ is decreased. Thus secratases are considered as the suitable target for AD therapy, among these, inhibition of BACE1 is promising. Although there are various BACE-1 inhibitors under investigation to treat AD, they suffer more limited therapeutic activity with *Address correspondence to this author at the Molecular Modeling and Drug Design Laboratory, Pharmacology Research Division, Bangladesh Council of Scientific & Industrial Research (BCSIR) Chittagong-4220, Bangladesh; Tel: +8801777447192; E-mail: smzahidhosen@bcsir.gov.bd mechanism-based abnormalities; as a result, safe and effective inhibitors are essential in AD management.
Leea indica (Burm.f.) Merr (Leeaceae), is a large evergreen shrub, commonly found in the tropical regions of Bangladesh, India, China, Bhutan, and Malaysia [8] . As a ethnomedicine, the leaves of L. indica are reported to have various medicinal values like antidysenteric, antispasmodic, anticancer, antidiarrheal properties [9] . Recently, Raihan et al. [10] described the significant sedative and anxiolytic potentiality of L. indica leaves, which encouraged us to hypothesize that L. indica extracts may have the potent molecules that are active against BACE1 enzyme, and therefore have the therapeutic values against Alzheimer disease. The main objective of this work was to find a potent inhibitor of BACE1 from the compounds derived from plant L. indica as a new therapeutics of Alzheimer disease.
MATERIALS AND METHODS

Compilation of Plant-derived Molecules of L. indica
For building an exclusive library of plant-derived compounds of L. indica, data regarding isolated compounds were assembled from literature and web resources, by searching with the keywords 'L. indica and 'Isolated Compound' to obtain relevant literature from international databases including, Web of Knowledge, PubMed, Google Scholar and Scopus. The spelling of each compound name was double checked and corrected using the existing compound databases from 'Pubchem' and 'ChemSpider'. Additional data regarding IUPAC (International Union of Pure and Applied Chemistry) name, plant part, chemical name, structural information were also collected. Compounds that are not available in web based re-sources were drawn and edited using Chemdraw and Biovia Draw, and also to check INCHE key and IUPAC name of the structure.
Preparation for Molecular Docking
In preparation for docking, ligand conformers were generated by MOE (Molecular Operating Environment, Chemical Computing Group, Ontario, Canada) [11] using the MOPAC module [12] . Using semiempirical methods, all compounds were geometrically optimized by using Hamiltonian PM3 basis set with RHF settings. Spin state was fixed to all and the gradient was 0.05 RMS kcal/mol A 2 .
Three-dimensional crystal structure of BACE1 was downloaded from the protein data bank (https://www.rcsb.org/) in pdb format (PDB ID: 5I3V). After that, using the steepest, descent and conjugate gradient technique, the model of beta-Secretase was subjected to energy minimization. By the implementation of Swiss-PDB Viewer, energy -19106.365 kj/mol and computations were done in vacuo with the GROMOS 96 43B1 parameters set without reaction field. Then the protein structure was prepared by the removal of water atoms and unnecessary residues.
Virtual Screening by Autodock Vina
Prior to the docking, the structures were prepared by using dock preparation wizard integrated in UCSF Chimera [13] , by adding hydrogen and Gasteiger charges [14] . Input ligand coordinates were further converted into pdbqt format by Python Molecular Viewer with AutoDock tools, required by AutoDock Vina [15] . The size of the grid box in AutoDock Vina was kept at 30.72, 25.00 and 25.00 respectively for X, Y, Z. The energy range was kept at 4 which was default setting. Autodock Vina was implemented through shell script provided by AutoDock Vina developers. The binding affinity of the ligand was observed by Kcal/mol as a unit for a negative score [16] .
Induced Fit Docking
Schrodinger's Induced Fit Docking (IFD) module was used for docking analysis with extra precision. Ligands are known often to induce conformational changes in the active site upon binding. The glide docking for ligand carried out individually by minimizing receptor with an RMSD constituting limit 18Å and box size was automatically generated. The van der Waals scaling factor was used to soften the potentials of the receptor and ligands both 0.50 and using B factor side chain were automatically trimmed. A maximum of 20 poses were saved. All residues of ligand poses were refined within 5.0Å using Prime molecular dynamics module for binding domain flexibility. Finally, the glide XP used for re-docking generated overall 20 structures within 30.0 kcal/mol of the best structure. For each ligand induced-fit receptor docking result yielded an IFD score.
Binding Free Energy Calculations
MOE software, version 2015 was introduced to calculate binding free energy using the scoring function of MM/GBVI. The generalized Born/volume integral (GB/VI) implicit solvent method was used to determine the binding affinities of the potential ligands, using the force field of Amber10:EHT with R-Field solvation [17] .
In addition, another calculation of binding free energy was performed by Prime MM-GBSA approach, where MM-GBSA is a method that combines OPLSAA molecular mechanics energies (EMM), an SGB solvation model for polar solvation (GSGB), and a non-polar solvation term (GNP) composed of the non-polar solvent accessible surface area and van der Waals interactions. Here, the Glide pose viewer file of the best conformation chosen was given as the source in Prime MM-GBSA simulation. The total free energy of binding: ΔG bind = G complex -(G protein + G ligand ), where G = EMM + GSGB + GNP
Steered Molecular Dynamics Simulation (SMD)
Steered molecular dynamics (SMD) simulation was performed by using YASARA dynamics package v16.9.23 on the proteinligand complexes to simulate relocation of bound ligands into the bulk solvent. Initially, each complex was subjected to further MD refinement using the YASARA software to 500 ps dynamics simulation at a temperature of 298 K, pH 7.4 and solvent density of 0.997. AMBER14 force field was utilized alongside keeping default the simulation parameters characterized by the macro. Then an initial 5ns classical MD simulation was run with parameters as described in [18] . After completing the 5 ns of classical molecular dynamics run, an accelerated steering force of 1000 pm/ps 2 (picometre/ picosecond square) was applied on the bound ligand in the protein complex. The force was directed from the geometric center of the receptor to the geometric center of the ligand. The steered simulation was stopped and analyzed at the point at which the ligand was displaced into and completely surrounded by hydrated counter ions. No part of the whole system was restrained during the production phase of steered molecular dynamics simulation or the initial molecular dynamics. Upon reaching the simulation end point, the resulting protein models and the simulation averaged structures were analysed by comparing it with the starting crystallographic structures and scored for backbone alpha-carbon (or side chain atom). The simulation trajectory was evaluated to find out variations in RMSD and Root mean square fluctuations (RMSF).
After that, MM-PBSA (Molecular mechanics-PoissonBoltzmann Surface Area) binding free energies of all snapshots were calculated with YASARA software using the following formula, Binding Energy = E potRecept + E solvRecept + E potLigand + E solvLigand -E pot-
Complex -E solvComplex
Here, YASARA built in macros was used to calculate MM-PBSA binding energy, using AMBER 14 as a force field, where resulted more positive energies indicate the better binding.
ADME/T Analysis
The pharmacokinetic profile of the lupeol and ursolic acid were calculated by QikProp module of Schrodinger Suit 2017-1 was utilized, where the absorption, distribution and metabolism of each ligand were calculated. Pharmacokinetics and the drug like properties of the ligands, such as the rate of oral absorption, CNS, logP, logPo/w, logHERG, Caco, LogBB, MDCK, percent of human oral absorption [19] .
RESULTS
Database and Virtual Screening
A total of 40 molecules have been identified and these are reported to be isolated and extracted from various parts of the plants with different extracts. The chemical compositions, IUPAC, Name and two dimensional figures are represented in Table S1 .
Out of 40 molecules, 16 (40%) molecules were reported from the flowers, while rest of 24 (60%) molecules were from leaves. Most compounds were reported from diethyl ether (40%) and petroleum ether (40%) extractions, while 1-butanol, methanol, ethyl acetate fraction were also used for isolating the compounds. Among the isolated compounds, L. indica predominantly constituted of essential oils and hydrocarbons, as observed from their phytochemical composition (Figure 1 a-c) . Other constituents like triterpenes, hydrocarbon, fatty acyls and sesquiterpenoids are also presented in this plant [9, 20, 21] In modern drug discovery process, virtual screening is one the most comprehensive approaches that have been used to find out the novel hits for a specific target from the databases of millions of compounds. AutoDock Vina is a program for virtual screening and molecular docking [22] . It imparts significant results of binding mode prediction with more accuracy and the binding affinity of ligand was observed by kcal/Mol as a unit for a negative score. All identified 40 compounds were subjected for docking studies (Figure 1d) ; of which, two compounds having lowest binding affinity are selected. Among these compounds, the highest docking score was found for ursolic acid (-10.1 kcal/mol) and the lowest docking score was -9.3 kcal/mol for lupeol.
Induced Fit Docking
Induced fit docking is a mix methodology of molecular docking and molecular dynamics simulations, which predicts more accurate bioactive confirmation than glide docking procedure. Therefore, both these compounds were considered for inducing fit docking, in which each compound resulted in more than 15 confirmations; confirmations with lowest induce fit docking scores were selected for further analysis ( Table 1) .
As illustrated in Figure 2, (Figure 3) . From a number of studies, it was found that the active site of BACE1 contains two aspartates, which are necessary for its proteolytic activity and represent the signature of the aspartyl protease class of enzymes, with these residues being included in canonical aspartyl-seryl/threonyl-gly-cyl motifs [23] . Most of the potent inhibitors of BACE-1 have been reported to be involved in hydrogen bonding with carboxylate side chain of ASP 32 and ASP 228 , thereby displace the water (WAT-1) molecule through destroying the hydrogen bonding network involving Asp32-Wat1-Asp228 [24, 25] . However, the docking analysis suggested that these compounds do not form any interactions with any these residues. Again, another important part of the inhibitors binding site, flap region; in which its conserved residues TYR71 involved in the hydrogen bonding with second water molecules (WAT-2) to facilitate appropriate orientation of flap region to bind with APP peptides to trigger the peptide bond cleavage [26] . Surprisingly, both these compounds exhibited hydrophobic interactions with TYR 71 through pi-alkyl bonding, thereby suggesting the destabilizing second water molecules. In addition, lupeol formed several pi -alkyl interactions residues of flap region (residues 67-77), concluding that lupeol strongly occupy the catalytic cavity of BACE1, and able to disrupt WAT-2 interactions of BACE1.
Binding Free Energy Calculations
As shown in Table 2 , the highest negative binding free energy in MM/GBVI solvation model was observed for lupeol (-44.28 kcal/mol), while ursolic acid showed the lowest negative binding free energy of -43.88 kcal/mol . Surprisingly, similar results were also observed in MM-GBSA approach, where lupeol also showed the highest binding free energy of -27.65 kcal/ mol; the binding energy was seen to be favored by the lipophilic term of binding energy and also by vdW energy. In addition, the binding energy of ursolic acid was seen to be supported by only Coulomb energy; however, it was not satisfactory to produce significant binding to BACE1.
Steered Molecular Dynamics Simulations
For describing true complex and also to improve binding energy predictions, 5ns classical molecular dynamics simulations have been performed with above describing simulated annealing energy minimization. During the simulations, every 10ps steps have been saved for further analysis. Initially, all steps from molecular dynamics simulations were subjected to RMSD analysis, where the value of the protein backbone of the complexes was calculated individually and plotted by comparing with the initial protein structure (shown in Figure 4) . High RMSD value represented the higher flexibility of the protein. As shown in Figure 4a , the values of RMSD were seen to fluctuate around the 1.5 Å for lupeol complex and tended to achieve equilibrium at 2.5 ns; remain stable afterward. In contrast, ursolic acid showed stable RMSD profiles around 1 Å, where the degree of magnitude was seen to fluctuate upward. The graphs clearly depicted that lupeol induced more flexibility than the ursolic acid; however, the proteins did not undergo conformational changes. In case of binding energy, MM-PBSA approach was accumulated to assess the binding free energy of the trajectory snapshots produced from the each complex during the simulations. As a result, binding energies of 500 snapshots were calculated and the results were plotted in Figure 4b , where positive values represent the better binding. According to the Figure 4b , the lupeol produced higher binding free energy (211.87 kj/mol) than the ursolic acid (-50.23 kj/mol), indicating much weaker or non-binding of ursolic acid towards the BACE1 enzyme.
To gain more insight into the residues contribution of BACE1 in ligand binding, steered molecular dynamics simulations of each complex were performed, in which each complex was taken from the last confirmation produced from classical molecular dynamics simulations. The results are plotted in Figure 5b , where the distance between the geometric centers of the protein and ligand as a function of simulation time, at a constant force. Interestingly, the puling time required for the ursolic acid from the protein was found to be greater than that for the lupeol complex. Although the results of MM/PBSA/GBSA/GBVI showed strong binding of lupeol, MM/PBSA and RMSF analysis have been executed to analyze the contribution of protein in ligand binding during the ligand dissociation. Therefore, RMSF of each protein in classical molecular dynamics and steered molecular dynamics were calculated and represented in Figure 6 , According to the Figure 6 , the fluctuations of the protein in two complexes were almost same in both simulations. Moreover, certain residues of the protein in both complexes highly fluctuated in molecular dynamics simulations, though these residues less fluctuated in steered molecular dynamics. Furthermore, both proteins residues were fluctuated at around 1Å. As 
Fig. (5).
Results of steered molecular dynamics simulations. a) Unbinding pathway of lupeol, here the green cartoon representation is BACE1 enzyme and lupeol is rendered in stick view. The red and blue color of ligand (in stick view) reprinting the intitial and final trajectory snapshots, which described how lupeol dissociated from BACE1 during the simulation. b) Dissociation time for lupeol and ursolic acid required in steered molecular dynamics simulation. The result showed as distance calculated between the receptor's centre of mass and the centre of mass of ligand. The green line for lupeol and blue for ursolic acid. C) Calculation of MM/PBSA binding energy of the two complexes during the steered molecular dynamics simulation, where green line for lupeol and blue for ursolic acid.
resulted from the docking simulation, the active site residues of both ligand protein complexes were carefully observed for RMSF values (Figure 7) . Surprisingly, the surrounding amino acids in the lupeol (Figure 7a ) fluctuated more in steered molecular dynamics while these less fluctuated during the molecular dynamics simulations. In contrast, the active site residues of ursolic acid (Figure 7b ) less fluctuated in both simulations, much less in steered molecular dynamics simulation. According to Figure 7a, concluding that the pulling force is not enough to pull out the ligand from the cavity. This statement is further validated by Figure 5c , showing the MM/PBSA binding free energy, calculated during the steered molecular dynamics.
ADME/T Analysis
Pharmaceutically relevant attributes and the physiochemical descriptors of the identified compounds were calculated by QikProp software, as the each descriptor's range satisfies 95 % of known drugs [27] [28] [29] . As described in Table S2 , showed all attributes calculated by QikProp for the compounds are in satisfactory range.
DISCUSSION
In AD therapy, there are five drugs are available in market for the treatment, including Tacrine, Donepezil, Rivastigmine, Galantamine and Memantine, however, these compounds inhibit the expression of acetylcholinesterase, which only reduces the symptoms and slows down the disease progression. Conversely, the inhibition of BACE1 is very promising, as it reduces the production of Aβ plaque in mice model [30, 31] . In this case, natural compounds modulate mitochondrial stress, apoptotic factors, free radical scavenging system, neurotrophic factors, and thus slow the disease progression by targeting multiple pathological causes. Moreover, plants containing phytochemicals have demonstrated to improve cognitive function by inhibiting the BACE1 [32] [33] [34] [35] . As shown in Table S1 , there are about 40 compounds till to date have been isolated from L. indica, and maximum of these from the leaves portion of the plant. In drug discovery pipeline, molecular docking is one of the most common techniques to identify potential inhibitors, substrates, activators or binding partners from compound libraries that contains a few hundreds to millions of compounds. According to the molecular docking analysis by Autodock Vina, two best hits having maximum binding affinity, including lupeol and ursolic acid have been identified. Since BACE1 conferred the flap flexibility [36, 37] , induced fit docking analysis was further incorporated, as it is a flexible docking simulation, which predicts accurate ligand binding modes and concomitant structural changes in the receptor [38, 39] . The docking analysis represented that both two compounds interacted with the second water binding site of BACE1, where lupeol showed strong hydrophobic interactions with the flap region. These results demonstrated the inhibition mechanism of lupeol and ursolic acid, which are also consistent with the previously published docking results [23, [40] [41] [42] [43] [44] [45] . Subsequently, the binding free energies of two complexes have been analyzed by MM-GBSA and MM/GBVI methods, and in both cases, lupeol showed better binding energies than ursolic acid. In molecular dynamics and steered dynamics simulations, lupeol produced higher flexibilities of the protein and also produced higher local fluctuations in the active site residues of the BACE1, which further concluded that lupeol binding is stronger than ursolic acid. Eventually, the binding interactions of ursolic acid were seen to unfavourable with BACE1, revealed by the steered dynamics simulation. However, the blood brain barrier transport is one of the main barriers for the development of lead molecule in CNS drug discovery, therefore, physicochemical and pharmacokinetics parameters of two molecules were calculated. Interestingly, lupeol showed better blood brain barrier abilities than the ursolic acid, and also the studies showed that lupeol process CNS activity (Table S2) . Furthermore, lupeol demonstrated well absorption rate and higher apparent Madin-Darby canine kidney (MDCK) cell permeability value, which used to make oral absorption estimates. Indeed, MadinDarby canine kidney cells also express transporter proteins, and also used as an additional criterion to predict BBB penetration (for non-active transport) [46, 47] . Finally, all molecular simulation studies suggested that the lupeol is potent enough to inhibit BACE1, and this result is also supported by the findings from the recent report of Koirala et al. [48] , where lupeol also inhibited BACE1 with IC 50 values of 5.12 µmol/L and also exhibiting a very potent inhibition with low inhibition constant (Ki) value of 1.43 mmol/L, demonstrating the greater binding affinity. In addition, lupeol was illustrated to protect mouse hippocampal cell lines HT-22 against glutamate toxicity [49] , and also suggested to potential as a neuroprotective agent in neurodegenerative diseases [49, 50] .
CONCLUSION
This computational study explored the lupeol as lead molecule from L. indica for BACE1 with detail binding mechanisms. The effectiveness of lupeol was clarified by the binding free energy analysis and molecular dynamics simulation, which is also consistent with recent experimental findings, and summarized the potentiality of the virtual screening protocol used in this study to identify potent inhibitor. The identified compound was found to occupy the catalytic flap region and may disrupt WAT-2 interactions of BACE1 enzyme. Moreover, lupeol can cross the blood brain barrier and also has less toxicity and a satisfactory oral absorption rate. In search of potent BACE1 inhibitor, this study could therefore provide insight for designing novel inhibitors, and reported compound can be a good source for developing novel therapies against the other targets of Alzheimer disease.
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